Regulatory challenges and market barriers in the approval of NASH/MASH treatment drugs.
NASH/MASH is a public health crisis that can lead to progressive liver fibrosis and cirrhosis. MASH is primarily associated with type 2 diabetes and cardiovascular diseases. Clinical trials need to demonstrate the ability of NASH treatments to slow disease progression and prevent onset by measuring composite endpoints related to liver-related outcomes. However, since there are currently no effective treatments for NASH, the U.S. FDA is providing an alternative approval pathway. This pathway relies on good clinical outcomes during trials, along with histopathological assessments of disease progression through liver biopsy as an alternative endpoint. Therefore, the U.S. FDA will approve drugs that meet the primary endpoint by demonstrating an improvement of more than one stage in fibrosis without worsening MASH or achieving resolution of MASH without worsening fibrosis. 【Contents】 ■ Market Overview ■ Market Analysis (by Drug Type, Clinical Pipeline, End User) ■ Regional Market Analysis ■ Company Profiles
Inquire About This Product
basic information
Publisher: Visiongain Publication Month: March 2025 Language of the Report: English *For more details, please visit our website or refer to the sample materials.
Price range
P4
Delivery Time
P2
Applications/Examples of results
In the survey report, we provide data that serves as the basis for corporate strategies and decision-making. You can check the delivery image from the sample. We can also introduce reports from our offerings that are closest to your preferences. Please feel free to contact us for any inquiries or consultations.
Company information
Data Resource Co., Ltd. provides valuable information and analytical data for business strategy planning, including the latest market information on telecommunications, computers, electronics, energy, and automotive-related sectors worldwide, as well as competitor strategies, the development of new technologies and services, regulations, and intellectual property.